Medisix Therapeutics

About Medisix Therapeutics

Medisix Therapeutics, founded in Singapore in 2016, is a clinical-stage immunotherapy company concentrating on the development of cellular therapies for cancer and infectious diseases. The company was established by Professor Dario Campana, a distinguished figure in the field of cell therapy, along with Celadon Partners and the National University of Singapore. Professor Campana's extensive background, which includes pioneering work on chimeric antigen receptor (CAR) technology at St. Jude Children's Research Hospital, provides a strong scientific foundation for the company's endeavors. Medisix Therapeutics is advancing a proprietary platform of immune-engineering technologies to create effective and safer cellular therapies. The company's primary focus is on developing treatments that can be administered without the need for prior chemotherapy, a significant differentiator that could reduce patient toxicity and expand the applicability of these therapies. Their lead products are built upon natural killer (NK) cells and T cells, which are engineered to target and eliminate malignant cells. This approach positions them within the competitive but rapidly growing cell and gene therapy market, serving patients with complex hematologic cancers and other challenging diseases. The company's business model revolves around the research, clinical development, and eventual commercialization of its therapeutic candidates. A key achievement in its history was the closing of a US$20 million financing round in February 2024, co-led by Lightstone Ventures and other prominent investors, designed to fund the initial clinical development of its lead programs in the United States. Medisix has established a cGMP manufacturing facility in Singapore, ensuring control over its production process, and is actively progressing its therapies through clinical trials. Keywords: cell therapy, immunotherapy, oncology, natural killer cells, CAR-T, clinical-stage, regenerative medicine, hematologic cancers, biopharmaceutical, gene therapy